Form 4: Altimmune Director Diane Jorkasky Awarded Options

Altimmune, Inc. director Diane Jorkasky has been granted 48,800 stock options as part of the company's standard non-employee director compensation policy.

Summary

• Diane Jorkasky, a member of the Board of Directors, received a grant of 48,800 stock options on May 1, 2026.
• The options carry an exercise price of $2.82 per share.
• Vesting occurs in 12 substantially equal monthly installments following the grant date.
• Full vesting is contingent upon continued service through each applicable vesting date.
• The options are scheduled to expire on May 1, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, administrative filing typical of public company operations, indicating standard board maintenance rather than a strategic shift.

Positives

• Aligns director interests with those of shareholders through equity-based compensation.
• The 12-month vesting schedule encourages short-to-medium term retention of board expertise.
• The exercise price of $2.82 establishes a clear threshold for value creation.

Negatives

• Represents a potential future dilution of 48,800 shares for existing shareholders.
• The options provide no immediate liquidity or value unless the stock price exceeds $2.82.

Risks

• The options may expire worthless if the company's share price remains below the $2.82 exercise price.
• Vesting is subject to continued service, posing a risk of forfeiture if the director departs the board prematurely.

Future Outlook

The grant ensures the director remains incentivized to oversee the company's strategic direction through at least May 2027, when the final tranche of these options is scheduled to vest.

Management Comments

• The options were granted pursuant to the Company's non-employee director compensation policy.

Industry Context

StockSavvy.ai notes that equity-heavy compensation for directors is a standard practice in the biotechnology sector, allowing cash-strapped or growth-oriented firms to attract high-level talent while preserving capital for research and development.

Comparison to Industry Standards

• The grant size of 48,800 options is consistent with annual director awards at peer biotechnology firms such as Viking Therapeutics and Madrigal Pharmaceuticals.
• A 12-month monthly vesting schedule is the industry standard for non-employee director equity grants.
• The 10-year expiration term is a typical duration for incentive stock options in the U.S. market.

Corporate Governance

Related Party Transactions

• The issuance of 48,800 stock options to Diane Jorkasky, a director of the company, constitutes a related party transaction under standard compensation policies.

Stakeholder Impact

• Shareholders: Potential for minor dilution of ownership percentage upon exercise of the options.
• Management/Board: Strengthened retention and incentive for a key director.

Next Steps

• Options will begin vesting in monthly increments starting in June 2026.
• The director must maintain service on the board to realize the full value of the grant.

Key Dates

Keywords

Altimmune, ALT, Insider Trading, Stock Options, Director Compensation, Biotechnology, SEC Form 4, Equity Grant